CCL2 and atherosclerosis: The CCL2 is upregulated significantly in retinas of diabetic animals, and it results in increased monocyte trafficking as well as activation of microglia.60 The CCL2 has been targeted in clinical trials in patients with atherosclerosis, diabetic nephropathy, chronic kidney disease, and diabetes itself.